1 M&E and ART programme Sri Lanka. 2 Overview of the presentation 1.NSACP service delivery points 2.Reporting units of ART programme 3.Recording and reporting.

Slides:



Advertisements
Similar presentations
Antiretroviral Therapy Standard Core Indicators. Emergency Plan for AIDS Relief 2 million people reached with ART 7 million new infects prevented 10 million.
Advertisements

Scaling up HIV services for women and children achievements and challenges e-lluminate session e-lluminate session Yves Souteyrand 2 March 2010.
Management of ART in Albania : From the European Guidelines to the real practice. Arjan Harxhi MD, MSc, PhD University Hospital Center of Tirana Mother.
HIV Situation in India Dr Sunil Gaikwad.
Rational Drug Use Supported by USAID Prescribing, Dispensing, Counseling and Adherence in ART Programs.
Indicators for monitoring ARV treatment outcomes.
Accessing to ARV in HIV/AIDS care and treatment programme in Vietnam Accessing to ARV in HIV/AIDS care and treatment programme in Vietnam Dr.Nguyen Van.
HIV Surveillance Report, 2001 Minnesota Department of Health HIV/AIDS Surveillance System Minnesota Department of Health HIV/AIDS Surveillance System.
Antiretroviral Therapy: An HIV Prevention Strategy? Wafaa El-Sadr, MD, MPH Columbia University Harlem Hospital New York.
Hellen Muttai, MBChB, MPH Clinical Care Manager
Sub module 2 Use of standardized records and registers.
June 2004 HITCH Training Slide Set #3 Special Considerations in Antiretroviral Therapy.
HYPnet Late presentation of vertically transmitted HIV infection in adolescence A Judd 1, R Ferrand 2,3, E Jungmann 2, C Foster 4, H Lyall 4, Brian Rice.
Clinical Research at JHP LNM – 02 October OutlineJHU- Administration Building History Influential studies- ◦ PEPI ◦ 052 Future Prospects.
Follow-up after training and supportive supervision The IMAI District Coordinator Course.
Loss to follow-up among women in Option B+ PMTCT programme in Lilongwe, Malawi: Understanding outcomes and reasons Hannock Tweya, Salem Gugsa, Mina Hosseinipour,
1 Cervical Screening Programme, England, : Graphs.
Texas Medical Monitoring Project (MMP) Meeting Omni Austin Hotel at Southpark Thursday, May 31, 2007 Local Questions for 2006.
Case 2: 40-year-old Woman with Long-standing HIV Infection
Women and HIV Roundtable Discussion on the Occasion of International Women’s Day 2010 “ Equal Rights, Equal Opportunities: Progress for All” Annami Löfving,
Pediatric Case Presentation BOGNON TANGUY Care Unit Children Exposed or Infected by HIV/AIDS Military Teaching Hospital - Cotonou - BENIN.
Risk factors and true outcomes of children lost to follow-up from antiretroviral therapy in Lilongwe, Malawi C. Ardura Gracia, H. Tweya, C Feldacker, S.
World Health Organization TB Case Definitions
Improving Retention, Adherence, and Psychosocial Support within PMTCT Services: Implementation Workshop for Health Workers All slide illustrations by Petra.
Integrated Monitoring and Evaluation of HIV Programs in Malawi Dr Andreas Jahn 1,2 1 Dept. for HIV and AIDS, MOH, Malawi 2 I-TECH Malawi.
Prescription and Use of Paediatric Antiretroviral Drugs (ARVs) for the Treatment of HIV in Children.
INTRODUCTION Sometimes Data Managers need a simplified way of knowing the clinical status as well as HIV patients management in their District Hospitals.
Prevention of Mother-to-Child Transmission of HIV in Ghana
Unit 5: IPT Isoniazid TB Preventive Therapy
ART Regimen Selection and Treatment Initiation for PMTCT Programs Lara Stabinski, MD, MPH Medical Officer Clinical Services S/GAC June 18, 2012.
PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV WHAT’S NEW Prepared by Dr. Debbie Carrington National HIV/AIDS Prevention & Control Programme Ministry.
Morbidity Monitoring Project Data for Resource Planning and Evaluation A.D. McNaghten Centers for Disease Control and Prevention.
Training course on Introducing pharmacovigilance into HIV/AIDS programmes Pretoria, South Africa, September 1-10,2004.
1 Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Extrapulmonary Site 2 :_____________________ Name (surname, first name) Age (in years) Sex F Alternative address Physical Address (in full) M INTERIM TUBERCULOSIS.
ICAP Quarterly Master Slide Set April-June Site Census What: Ongoing, real-time inventory of all planned, current, and closed ICAP sites. Supported.
Clinical Tracking and Management of HIV-Positive Children National Pediatric HIV Training 1.
1 Antiretroviral Therapy in HIV-infected Children HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Office of Overseas Programming & Training Support (OPATS) Treatment Adherence HIV Care, Support, and Treatment.
Orientation on HIV care and ART Recording and Reporting System.
Unit 12: Reporting & Recording Botswana National Tuberculosis Programme Manual Training for Medical Officers.
EARLY CHILDHOOD OUTCOMES AT THE BOTSWANA- BAYLOR CHILDREN’S CLINICAL CENTRE OF EXCELLENCE: A REPORT TO THE WHO TECHNICAL REFERENCE GROUP ON PEDIATRIC CARE.
1 Monitoring The Patient on ARV Treatment HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Clinicopathologic Conference Advanced Update in HIV Medicine and Clinical Research October 1, 2009 Tammy M. Meyers, BA, MBBCh (WITS), FCPaed (SA), Mmed,
TB R&R System's strong points
-IAA The Dispensing Based Retrospective Data Collection Adherence Assessment Survey Dispensing 1.
Extrapulmonary Site 2 :_____________________ TUBERCULOSIS TREATMENT CARD BOTSWANA NATIONAL TUBERCULOSIS PROGRAMME Date RegisteredIN ToOUT RegisteredIN.
1 HIV Clinical Staging HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Comprehensive Field Record. Introduction to the Training ● The slides will first show a picture of the section of the template that will be discussed.
MISSING DATA IN THE INFECTIOUS DISEASES INSTITUTE CLINIC DATABASE Agnes N Kiragga East Africa IeDEA investigators’ meeting 4-5 th May 2010 East African.
Comprehensive Field Record. Introduction to the Training ● The slides will first show a picture of the section of the template that will be discussed.
Module 3: Management of Patients on Antiretroviral Therapy Unit 2: Initiation and Monitoring of ART in Adults and Adolescents.
Unit 11 Drug Resistance and MDR-TB: B Family Case Botswana National Tuberculosis Programme Manual Training for Medical Officers.
Sub module 1 Introduction to HIV care and ART recording and reporting system.
Scale up TB/HIV activities in Asia Pacific 8-9Aug09 1 TB/HIV collaborative activities in Thailand Sriprapa Nateniyom, M.D. TB Bureau, Department of Disease.
1 Management, Care for infants who were born from infected mothers HAIVN Harvard Medical School AIDS Initiatives in Vietnam.
Sub module 3 Pre-ART and ART registers. Purpose of registers Key individual information for: Facilitating patient management by the identification of.
Antiretroviral treatment programme in Thyolo district, Malawi Southern Region. MSF Luxembourg & Thyolo District Health Services - Strategic information.
Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.
ICAP Quarterly Master Slide Set July-September 2007.
MATERNAL ANTIRETROVIRAL THERAPY AND INFANT OUTCOMES THROUGHOUT THE FIRST YEAR OF LIFE: results from the DREAM study in Dschang, Cameroon Taafo F, Doro.
1 Uses of Data from the WHO HIV Drug Resistance Strategy: 1. Monitoring of HIVDR emerging in treated groups in sentinel ART clinics HIV Drug Resistance.
Response to Antiretroviral Treatment In an Ethiopian Hospital Samuel Hailemariam, MD, MPH; J Allen McCutchan, MD, MSc Meaza Demissie, MD, PMH, PHD; Alemayehu.
Improving Patients Retention in Antiretroviral Treatment Programs: The experience of ARV Programs in Côte d’Ivoire Eugène MESSOU, MD, PhD CePReF- Aconda.
1 Predictors of Immunological Failure Among Adult Patients Receiving ART at an urban, HIV Clinic in Uganda Dr. Muhumuza Simon (M.D, MPH) Mulago-Mbarara.
Guidance on completion of Isoniazid Preventive Therapy register
TB- HIV Collaborative activities in Romania- may 2006 status
Better Retention Rates Observed in Patients on Lopinavir than Atazanavir in Uganda
monitoring & evaluation THD Unit, Stop TB department WHO Geneva
Monitoring of Antiretroviral therapy (ART)delivery by Regional Tuberculosis Officers (RTO) in Malawi: Rhehab Chimzizi Anthony Harries Edwin Libamba Maxwell.
Presentation transcript:

1 M&E and ART programme Sri Lanka

2 Overview of the presentation 1.NSACP service delivery points 2.Reporting units of ART programme 3.Recording and reporting system 4.Pre-ART register 5.ART register 6.Examples and register studies

Service delivery points NSACP Service delivery points No 1Full time STD clinics29 2Branch clinics16 3IDH1 NSACP ART centersCode 1Central clinic, ColomboCO 2STD clinic, KalubovilaKB 3STD clinic, RagamaRG 4STD clinic, KandyKA 5IDH

ART reporting centres

ART programme– National STD/AIDS control Programme.

STI surveillance – (a). National STD/AIDS control Programme.

Recording forms 1. Patient HIV Care and Antiretroviral Treatment (ART) Record (Patient HIV Care/ART Record) 2. Pre-ART Register 3. ART Register 4. ARV Drug Dispensing Register 5. ARV Drug Stock Register.

Reporting forms 1. The Monthly HIV Care/Antriteroviral Treatment (ART) Centre Report (ART Monthly Report) 2. Treatment Outcomes for Cohorts on ART (Cohort Analysis Report).

ART monitoring and evaluation

Pre-ART register

Pre-ART Register The purposes of the pre-ART Register are to document: Routine performance indicators 1.The cumulative enrolment in HIV care, by sex and age; 2.The cumulative number medically eligible for ART but have not been started on ART, by sex and age; More in-depth analysis 1.Socio economic profile of people accessing HIV care and starting ART; 2.Services which refer the patients for HIV care and in particular, the number and proportion of patients 3.referred from TB services; 4.Access to care and ART for the most vulnerable high risk groups (sex work and injecting drug use); 5.Occurrence of TB among patients enrolled and not started on ART; 6.Criteria routinely used for medical eligibility to ART; and 7.Profile of persons who died or were lost to follow-up before starting ART.

The pre-ART Register has to be completed: 1.At the first visit for most of the information (column 1 to 10); 2.at the start of cotrimoxazole preventive therapy (column 11); 3.at the start of TB treatment (column 12); 4.at medical eligibility for ART (column 13-14); 5.at start of ART (column 15); and 6.whenever follow-up was ended before ART was started (columns 16). For a patient starting ART, the Pre-ART Register does not have to be used once the date of start has been recorded; all their information will now be recorded in the ART Register.

ART register

ART Register The purposes of the ART Register are to document the following 1/2: Routine performance indicators 1.The number started on ART during the period, by sex and age; 2.The cumulative number ever started on ART, by sex and age; 3.The cumulative number on treatment, by sex and age; 4.The time point outcomes of the cohort of patients who started ART (stop, lost to follow-up, transferred out, dead); 5.The cumulative number on substituted 1st line regimen; 6.The cumulative number on 2nd line regimen; 7.Regimen prescribed at the end of a period; 8.The proportion of people with more than 95% adherence; 9.The proportion of people alive and on treatment at 6, 12 and 24 months after start of treatment; 10.The change in CD4 count at 6,12, 24 months of ART; 11.The proportion of people whose performance status at 6, 12, 24 months is "normal working";

Patient management 1.Identification of patients lost to follow-up 2.Identification of patients who missed appointments In-depth analysis 1.Survival on treatment according to sex, age, initial regimen and prior exposure to ARV 2.Occurrence of TB among patients on ART 3.Reasons for substituting and switching regimen; and 4.Frequency of substituting and switching according to initial regimen started, gender, age and prior exposure to ARV. The ART Register has to be completed for all patients starting ART, during all monthly follow-up visits since the date of starting treatment to the end of follow-up on ART. ART Register The purposes of the ART Register are to document the following 2/2:

Examples/Register studies

Register study 1: Ms A (registration number CO/F/124), is 24 years old and started D4T/3TC/NVP on 12th December At this time she had stage IV disease, and was bedridden more than half of the day during the previous month. Her weight was 41 kg for a height of 163 cm. TLC was 800 cells/mm3. She had never received ART before and no CD4 tests were performed. She came every month during 2004 and reported more than 95% adherence always. After 6 months on treatment she was able to work again, and her weight increased to 45 kg. She had 156 CD4 cell count on investigation at 6 months. In December 2004, for the visit at 12 months, she was still working and the CD4 examination showed 208 cells. Her weight was 47 kg. She did not miss any doses and the same treatment was continued.

Register study 2: Mr B, who is 33 years old, was transferred out on 5th December 2004 to clinic ID for follow-up under ART. He started ART in the national programme at clinic CO, 7 months ago on 1st May 2004 (registration number CO/M/ 0256). At the start of ART he was in stage III disease, and weighed 65 kg for a height of 175 cm. He had 145 CD4, and was working. He had been taking ART before starting treatment in the national programme (he was able to afford 3 months dual therapy ddC/AZT in 2003). He was started on D4T/3TC/NVP and was followed-up every month with more than 95% adherence. At 6 months on examination he was found to have 210 CD4 and his weight was 66 kg. The 1st visit to clinic ID was his 7th month follow- up visit. He reported having missed more than 3 doses of ART (he missed 5 days ART because of moving). The same regimen was continued at clinic ID.

Register study 3: Mr C is 40 years old (registration number KB/M/098) and was started on ART 3 months ago on 6th September He had stage IV disease and CD4 at 32. His weight was 54 kg for a height of 169 cm. He was bedridden for less than half part of the day. He had not previously taken ARVs and was started on D4T/3TC/NVP. On the 2nd follow-up visit for ART, he reported not having missed any doses. He complained about productive cough, asthenia, and night sweats. He was referred to the TB centre, where a diagnosis of smear-positive pulmonary TB was made. ART treatment was stopped and TB treatment started on 17th October (regimen category I). He came for monthly appointments and ART was restarted in December 2004 with D4T/3TC/EFV, once the TB treatment was well- tolerated.

Register study 4: Ms D is 36 years old (registration number RG/F/020) and started ART on 15th June She had stage III disease with CD4 at 79. Her weight was 56 kg for a height of 162 cm. She was working. She had taken NVP for PMTCT a year ago. She lives quite far (2 hours drive from the clinic), has lost her husband and has to take charge of two children (HIV negative) alone. On the visit at 2 weeks, she said not having missed any ART doses. At one month she missed more than 3 doses of ARV, because she came late for her scheduled appointment as one child was sick. The month after, she reported poor adherence (<80%) due to gastro intestinal side effects. Since 15th August 2004, she had not returned to clinic RG and has been reported as lost to FU in December 2004 as she has been missing for more than 3 months.

THANK YOU ART programm has only few registers